网络Meta分析:溃疡性结肠炎先进治疗的组织学与组织内镜改善及缓解
该网络Meta分析纳入24项随机对照试验(15种疗法,8874例患者),比较生物制剂和小分子药物在中重度溃疡性结肠炎中的组织学终点。诱导期依曲莫德2 mg/天在组织学改善和缓解方面排名最高;维持期乌帕替尼30 mg/天在组织学改善、缓解及组织内镜改善方面均最优。作者认为结果支持小分子药物实现严格终点,但生物制剂组织学数据较少,需头对头试验。
要点
- 诱导期依曲莫德2 mg/天组织学改善P-score 0.98、缓解P-score 0.90,均排名第一。
- 维持期乌帕替尼30 mg/天组织学改善和缓解P-score均为0.88,组织内镜改善P-score 0.94。
- 生物制剂组织学结局数据较少,尤其在维持期,作者认为需头对头随机对照试验。
核心结论
- 结果支持小分子药物在中重度溃疡性结肠炎中实现严格终点。
- 生物制剂的组织学结局数据较少,尤其在维持期。
- 作者认为需头对头随机对照试验以更好指导临床实践。
研究设计与样本
- 网络Meta分析,检索四个数据库至2024年7月,纳入中重度溃疡性结肠炎先进治疗的随机对照试验。
- 共纳入24项随机对照试验,涉及15种疗法、8874例患者;19项提供诱导期数据,10项提供维持期数据。
- 采用随机效应频率学模型,报告相对危险度和95%置信区间,用P-score估计相对疗效,按试验阶段进行亚组分析并评估偏倚风险和证据确定性。
主要发现
- 诱导期依曲莫德2 mg/天在组织学改善(P-score 0.98)和缓解(P-score 0.90)方面排名最高。
- 总体分析中古塞奇尤单抗200-400 mg在组织内镜改善方面排名第一,亚组分析中依曲莫德2 mg/天和乌帕替尼45 mg/天更优。
- 维持期乌帕替尼30 mg/天在组织学改善和缓解(P-score均为0.88)及组织内镜改善(P-score 0.94)方面更优。
- 维持期依曲莫德2 mg/天在组织学缓解(P-score 0.70)和组织内镜改善(P-score 0.73)方面排名第二,米吉珠单抗200 mg/月在组织学改善方面排名第二。
关键数值与推荐
- 诱导期组织学改善P-score:依曲莫德2 mg/天0.98(排名最高)。
- 诱导期组织学缓解P-score:依曲莫德2 mg/天0.90(排名最高)。
- 维持期组织学改善和缓解P-score:乌帕替尼30 mg/天均为0.88(排名最高)。
- 维持期组织内镜改善P-score:乌帕替尼30 mg/天0.94(排名最高)。
- 维持期组织学缓解P-score:依曲莫德2 mg/天0.70(排名第二)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 生物制剂的组织学结局数据较少,尤其在维持期。
- 作者认为需头对头随机对照试验以更好指导临床实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Histology has prognostic value in ulcerative colitis (UC). However, direct comparisons of histological endpoints are lacking. AIM: To perform a network meta-analysis (NMA) to compare histological endpoints with biologics and small molecules. METHODS: We searched four databases up until July 2024 for randomised controlled trials (RCTs) on advanced therapies for moderate-to-severe UC reporting histological endpoints. Outcomes included histological improvement or remission, and histo-endoscopic improvement after induction or during maintenance. We used a random-effects frequentist model and have reported outcomes as relative risk and 95% confidence interval. We estimated relative drug efficacy with the P-score. We conducted subgroup analysis by trial phase and evaluated risk of bias and evidence certainty. RESULTS: We included 24 RCTs (15 therapies, 8874 patients). Nineteen provided data on induction and 10 on maintenance; outcome definitions were similar. Etrasimod 2 mg/day ranked highest in achieving histologic improvement (P-score 0.98) and remission (P-score 0.90) following induction. Globally, guselkumab 200-400 mg ranked first for histo-endoscopic improvement, while etrasimod 2 mg/day and upadacitinib 45 mg/day were superior in the subgroup analysis. During maintenance, upadacitinib 30 mg/day was superior in achieving histologic improvement and remission (P-score 0.88 for both) and histo-endoscopic improvement (P-score 0.94). Etrasimod 2 mg/day ranked second for histologic remission (P-score 0.70) and histo-endoscopic improvement (P-score 0.73), while mirikizumab 200 mg/month ranked second for histologic improvement. CONCLUSION: These results support the ability of small molecules to achieve stringent endpoints in moderate-to-severe UC. Histological outcome data for biologics was sparser, particularly during maintenance. Head-to-head RCTs are imperative to better inform clinical practice.
引用
- Estevinho MM, Sousa-Pinto B, Moreira PL, et al. Network Meta-Analysis: Histologic and Histo-Endoscopic Improvement and Remission With Advanced Therapy in Ulcerative Colitis. Aliment Pharmacol Ther. 2024. PMID: 39367678. doi:10.1111/apt.18315
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。